COMP <GO>
VRAX vs CDIO // EV/EBITDA & P/E VALUATION
Virax Biolabs Group Limited (NASDAQ) VS. Cardio Diagnostics Holdings Inc. (NASDAQ) • 15-METRIC TALLY: VRAX 0
— CDIO 2
■ METRIC PARITY
LAST: $1.32 (+10.00%) • MKT CAP: $1.8M
valuation
—
LAST: $1.75 (+2.94%) • MKT CAP: $5.2M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VRAX VS. CDIO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VRAX | CDIO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -57.50% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 3/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 27.1 | 41.0 | -13.95 | CDIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.8M | $5.2M | -$3.4M | CDIO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VRAX REV | CDIO REV | VRAX GROSS % | CDIO GROSS % | VRAX FCF | CDIO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $14.8K | — | — | — | -$5.9M |
| FY 2024 | — | $34.9K | — | — | — | -$5.2M |
| FY 2023 | — | $17.1K | — | — | — | -$5.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VRAX // BETA —
CDIO // BETA —